These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 14498755)

  • 21. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopeptidase inhibitors: will they have a role in clinical practice?
    Worthley MI; Corti R; Worthley SG
    Br J Clin Pharmacol; 2004 Jan; 57(1):27-36. PubMed ID: 14678337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.
    Hanif K; Bid HK; Konwar R
    Hypertens Res; 2010 Jan; 33(1):11-21. PubMed ID: 19911001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE inhibitors. Differential use in elderly patients with hypertension.
    Israili ZH; Hall WD
    Drugs Aging; 1995 Nov; 7(5):355-71. PubMed ID: 8573991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
    Bavishi C; Messerli FH; Kadosh B; Ruilope LM; Kario K
    Eur Heart J; 2015 Aug; 36(30):1967-73. PubMed ID: 25898846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
    Laurent S; Boutouyrie P; Azizi M; Marie C; Gros C; Schwartz JC; Lecomte JM; Bralet J
    Hypertension; 2000 May; 35(5):1148-53. PubMed ID: 10818079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action.
    Dietz R; Waas W; Süsselbeck T; Willenbrock R; Osterziel KJ
    Circulation; 1993 May; 87(5 Suppl):IV108-16. PubMed ID: 8485825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.